Drug Policy Watch · State Brief 2026

Washington

Snapshot (structured)

Adult-use cannabis: Legal, voter-approved by Initiative 502 in 2012, regulated retail sales since 2014.
Medical cannabis: Legal, integrated into the state-regulated system, medically endorsed retail stores serve qualifying patients, medical sales exempt from the cannabis excise tax.
Home grow: Banned for adult recreational use, Washington is one of the few legal adult-use states that prohibits personal home cultivation, only qualifying medical patients may grow limited plants. The 2026 home grow bill (SB 6204) did not pass.
Intoxicating hemp / hemp THC: Heavily restricted, under SB 5367 (2023) any product with detectable THC must be sold through a WSLCB-licensed cannabis retailer, which functionally bars hemp-derived intoxicants (delta-8, delta-10, hemp delta-9, HHC) from general retail.
Psychedelics: Not decriminalized, a limited psilocybin therapy pilot for veterans and first responders exists at the University of Washington, broader medical psilocybin bills proposed in 2026 did not pass.
Broad decriminalization: No, Washington recriminalized simple drug possession (gross misdemeanor) in 2023 after the State v. Blake decision, with a treatment-diversion emphasis.
Harm reduction: Strong, legal syringe services, broad naloxone access, fentanyl test strips legal and distributed.
Governor (party): Bob Ferguson (Democratic), took office January 13, 2025.
Legislature control: Democratic trifecta, Democrats hold both chambers (reported roughly 30-19 Senate, 59-39 House).
Citizen ballot initiatives allowed: Yes, Washington allows citizen initiatives (initiative to the people and initiative to the legislature).
Enclosure pressure score: 4/5

Cannabis

Washington legalized adult-use cannabis in 2012 via Initiative 502, one of the first two states to do so alongside Colorado, with regulated retail sales beginning in 2014. Medical cannabis is legal and has been folded into the state-regulated system, qualifying patients can register and shop at medically endorsed retailers, and medical sales are exempt from the cannabis excise tax (see Harris Sliwoski).

Home grow remains the conspicuous gap. Washington bans personal home cultivation for adult recreational use, making it one of the only legal adult-use states without home grow, while qualifying medical patients may grow a limited number of plants (MPP, Triangle Hemp). In the 2026 session, SB 6204 would have allowed adults 21 and over to cultivate up to six plants (no more than 15 per housing unit regardless of occupant count), with plants kept out of public view. The bill advanced out of the Senate Labor and Commerce Committee in early February 2026 but stalled, it was in the Senate Rules "X" file as of late February 2026 and did not pass before the session adjourned (Axios, WA Legislature SB 6204, Marijuana Moment). Opposition has centered on protecting retail tax revenue, with cannabis retailers and trade associations lobbying against home grow.

Note on SB 6204 sponsorship: sources conflict. One legislative-tracking summary lists sponsors as Senators Saldaña, Frame, and Nobles, while a Marijuana Moment report references Senate approval of a home grow measure. Treat exact sponsor attribution as partly unconfirmed and verify against the official bill page.

Market structure: Washington carries the nation's highest cannabis excise tax at 37 percent, layered on top of the 6.5 percent state sales tax and local sales taxes, producing an effective consumer rate often cited around 44 to 50 percent (Washington Cannabis). Retail licenses are capped (commonly reported around 500 statewide) and the state has generally not issued new general retail licenses outside the social equity program (Hefestus). Exact current licensee counts and residency-requirement specifics were not confirmed in this round of research and should be verified with the WSLCB.

Hemp

Washington tightly restricts intoxicating hemp. Under SB 5367 (2023), any product with detectable THC must be sold through a WSLCB-licensed cannabis retailer, which functionally bars hemp-derived intoxicants (delta-8, delta-10, hemp-derived delta-9, HHC, THC-O) from general retail and convenience channels. Operators outside the licensed cannabis channel must keep total THC below detection limits in finished products (HempData, washingtonstatecannabis.org).

On the federal side, Congress narrowed the federal definition of hemp in legislation signed in late 2025, imposing strict total-THC-per-serving caps that are widely reported to effectively ban most consumable intoxicating hemp products nationwide. Multiple sources cite an effective date of November 12, 2026 for the new federal hemp restrictions (Regulatory Oversight, Manzuri Law, Wilson Elser). For Washington, the practical impact is muted, because the state's channel restriction (SB 5367) already blocks most hemp intoxicants from general retail, so the binding constraint inside the state is the state law rather than the federal serving cap. The exact federal bill citation and the precise serving-cap figure circulating in trade coverage (often quoted as 0.4 mg total THC per serving) should be treated as unconfirmed pending the final enacted text.

Psychedelics

Psychedelics are not decriminalized in Washington. The state's main therapeutic-access vehicle is the Washington Psilocybin Services Act (SB 5263, 2023), sponsored by Senators Jesse Salomon (D) and Liz Lovelett (D) and signed by then-Governor Jay Inslee in May 2023. The enacted version was substantially scaled down, limiting access to military veterans and first responders, conditioning services on FDA-approved psilocybin therapy, and establishing a University of Washington pilot program (target operation by January 1, 2025). Inslee's partial veto cut the proposed psilocybin advisory board and interagency work group, leaving a psilocybin task force (Marijuana Moment, Filter, WA bill report 5263-S2).

For 2026, Senator Salomon prefiled SB 5921 (prefiled December 19, 2025), which would create a state-regulated "Washington medical psilocybin act" under the Department of Health, licensing clinicians and producers and maintaining a confidential patient registry, with a reported effective date of July 1, 2028 if enacted (The Marijuana Herald, LegiScan SB 5921 text). A separate measure (reported as SB 5201) and other psychedelic proposals were also tracked in the 2025-2026 biennium. None of these broader psilocybin measures are reported to have passed before the 2026 session adjourned sine die on March 12, 2026, treat their final status as inactive for 2026 and verify on the live tracker.

Broader drug policy

Decriminalization and the Blake aftermath: On February 25, 2021, the Washington Supreme Court in State v. Blake struck down the state's simple drug possession statute as unconstitutional because it criminalized unknowing possession, voiding past convictions (ACLU-WA Q&A). After a stopgap (ESB 5476), the legislature passed SB 5536, the "Blake fix," signed by Governor Inslee on May 16, 2023 and effective July 1, 2023. SB 5536 recriminalized knowing possession and public use as a gross misdemeanor, punishable by up to six months in jail and a $1,000 fine for the first two offenses and up to 364 days thereafter, while emphasizing pretrial diversion and treatment (MRSC, NWSidebar). This is effectively a recriminalization with a treatment-first overlay, not full decriminalization.

Record relief and refunds: Blake-related convictions qualify to be vacated, and the state set aside roughly $100 million to reimburse fines, court costs, and legal fees, with an online reimbursement portal (NORML).

Harm reduction: Washington has a robust harm-reduction infrastructure. Syringe service programs operate legally (for example The People's Harm Reduction Alliance), naloxone is broadly available (free at pharmacies for Apple Health/Medicaid enrollees with no prescription, plus mail order and vending machines), and fentanyl test strips are legal and widely distributed. In 2024 the legislature passed 2SHB 2112 requiring higher-education institutions to provide naloxone and fentanyl test strip education and access (King County, WA bill report 2SHB 2112, DOH fentanyl test strip guidance).

Political landscape

Governor: Bob Ferguson (Democratic), in office since January 13, 2025 (Ballotpedia). Washington is a Democratic trifecta, with Democrats controlling both chambers (reported roughly 30-19 in the Senate and 59-39 in the House) (Ballotpedia, party control).

Named reform figures: Sen. Jesse Salomon (D) and Sen. Liz Lovelett (D) have championed psilocybin therapy access (SB 5263, and Salomon's 2026 SB 5921). Rep. Nicole Macri (D) expanded the 2023 psilocybin bill via committee amendment to add the UW pilot for veterans and first responders (Marijuana Moment). On cannabis home grow, the lead 2026 sponsors are reported but not fully confirmed (see SB 6204 note above). Key committees for these issues include the Senate Labor and Commerce Committee (cannabis/home grow) and the health-policy committees (psilocybin). Named opponents of home grow are primarily the cannabis retail trade associations rather than individual named legislators, treat specific opponent names as unconfirmed.

Ballot initiatives

Washington allows citizen-initiated ballot measures, both the initiative to the people (direct to the ballot) and the initiative to the legislature. Adult-use legalization itself came through Initiative 502 in 2012. As of this brief, no statewide cannabis, psychedelic, or drug-policy citizen initiative is confirmed as qualified for a 2026 ballot, treat any such measure as unconfirmed pending the Secretary of State's filings. Most 2026 drug-policy activity moved through the legislature rather than the ballot.

Equity and expungement

Washington runs a Cannabis Social Equity Program through the WSLCB. Rules for the next licensing round took effect January 18, 2025, and in the June 2025 eligibility round, 880 registrants applied for 69 available retail licenses, registration is free with fees due later for those who advance (WSLCB Social Equity FAQ, WSLCB Cannabis Social Equity). The heavy oversubscription (880 applicants for 69 licenses) shows demand far exceeds the capped supply, so most equity applicants are excluded by scarcity even though the program exists.

Expungement: Through the Marijuana Justice Initiative, people 21 or older convicted of misdemeanor marijuana possession can petition the sentencing court to vacate the conviction (petition-based, not fully automatic). Separately, Blake-related drug possession convictions qualify to be vacated, with refunds available for fines and fees via a state portal backed by roughly $100 million (Point Seven Group, NORML).

Market and barriers

Cannabis excise tax: 37 percent, the highest state cannabis excise rate in the nation, plus 6.5 percent state sales tax and local sales tax (0 to roughly 3.9 percent), effective consumer rate commonly cited at 44 to 50 percent (Washington Cannabis).
Medical exemption: medically endorsed sales to registered patients are exempt from the 37 percent excise tax.
Retail license cap: commonly reported around 500 statewide, with general new-license issuance frozen outside the social equity rounds (Hefestus).
Social equity round: 69 retail licenses offered in the 2025 round, 880 registrants.
License fees, capital requirements, residency requirements, and the current exact count of active licensees were not confirmed in this research and should be verified directly with the WSLCB.

Enclosure read

Washington is fairly heavily fenced. The structure rewards incumbents and the state's tax base while fencing out small and new entrants on multiple fronts. Adults cannot grow their own cannabis (home grow stays illegal, and the 2026 attempt died), so the only legal path to flower runs through a capped, taxed retail system carrying the highest excise rate in the country. The retail license cap (around 500) plus a frozen general-issuance pipeline means new operators mostly enter only through a heavily oversubscribed social equity lottery (880 applicants chasing 69 licenses). On hemp, SB 5367 routes any detectable-THC product into the same licensed channel, fencing independent hemp brands out of general retail. Harm reduction and Blake-related record relief pull in the opposite (more open) direction, and an active reform bloc keeps pushing home grow and psilocybin access, which is why this is a 4 and not a 5. The dominant trend, though, is consolidation around licensed incumbents and protected tax revenue, with the little guy fenced out of cultivation, hemp retail, and scarce licenses.

Enclosure pressure score: 4/5.

What to watch next

2026 session adjourned sine die March 12, 2026, the 90-day effective date for enacted 2026 bills is reported as June 11, 2026.
Next regular session: the 2027 long session convenes in January 2027 (the typical odd-year long session), where home grow (SB 6204 successor) and medical psilocybin (SB 5921 successor) are likely to return, verify dates with the legislature.
Federal hemp deadline: November 12, 2026 is the widely cited effective date for the narrowed federal hemp definition and THC serving cap, watch for any WSLCB conformance rulemaking, though state channel rules already dominate.
UW psilocybin pilot: track implementation and any task force reports that could shape future therapeutic-access bills.
WSLCB social equity licensing: watch the next equity round and any rulemaking petitions (for example the December 2025 qualified-remnants petition).
Ballot: watch Secretary of State filings for any 2026 citizen initiative touching drug policy (none confirmed as of this brief).

Regulators

Washington State Liquor and Cannabis Board (WSLCB / LCB): licenses and regulates cannabis production, processing, and retail, administers and collects the cannabis excise tax, and runs the cannabis social equity program (lcb.wa.gov).
Washington State Department of Health (DOH): naloxone and harm-reduction guidance, and the proposed regulator for any medical psilocybin program under SB 5921.
University of Washington (Addictions, Drug and Alcohol Institute and related units): host of the psilocybin therapy pilot program.
WSLCB also regulates the THC-channel restriction affecting hemp-derived intoxicants under SB 5367.

Federal exposure (2026)

Washington sits at one of the sharpest gaps between state legality and federal posture, because its market is overwhelmingly adult-use recreational, the category federal action in 2026 does the least for.

Rescheduling and 280E. Cannabis remains Schedule I by default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, ending Section 280E for that narrow medical category, while recreational cannabis stays Schedule I (DEA scheduling overview). For Washington this is mostly a non-event on the ground. The state runs a single integrated system where medical sales flow through medically endorsed retailers, but the overwhelming bulk of licensed activity is recreational, so most Washington operators get no 280E relief and keep losing the federal deduction for ordinary business expenses. Layer that on the squeeze already built into state law: Washington carries the nation's highest cannabis excise at 37 percent, plus 6.5 percent state sales tax and local rates, so an operator pays an effective consumer-facing rate near 44 to 50 percent and then, on the recreational side, cannot deduct normal costs against federal income because of 280E. The medical carve-out is real but thin here, because medical is already excise-exempt and is a small slice of the integrated market, so the 280E relief reaches few Washington businesses. Schedule III does not legalize cannabis, does not open interstate commerce, and does not cover state recreational businesses, so Washington's capped, high-tax retail model stays fully exposed to the federal tax penalty that most punishes the smaller-margin operators.

Hemp cliff (November 12, 2026). FY2026 agriculture appropriations (Sec. 781, sponsor reported as Rep. Andy Harris R-MD, verify on the enacted text) narrowed hemp to a total-THC standard (reported as about 0.4 mg THC per container), recriminalizing roughly 90 to 95 percent of intoxicating hemp products effective November 12, 2026. A standalone delay measure (reported as H.R.7010, unconfirmed, verify on congress.gov) was not enacted, and the 2026 Farm Bill (reported as H.R.7567, unconfirmed) keeps the ban. For Washington the federal ban largely aligns with state law rather than disrupting it, because SB 5367 already routes any detectable-THC product through WSLCB-licensed cannabis retailers, so hemp-derived intoxicants are already fenced out of general retail. The practical effect: independent hemp brands that were surviving in gray channels lose their federal cover too, the binding constraint stays the state channel rule, and the federal cliff simply closes the few remaining national pathways (interstate shipment, online sales into Washington) without changing what a Washington consumer can buy in a store.

Banking. SAFER Banking remains stalled in Congress, so Washington's licensed operators stay locked out of normal banking, card processing, and lending, a cash-heavy burden that compounds the 280E and high-tax squeeze and falls hardest on undercapitalized social equity entrants (NCSL cannabis overview).

Psychedelics. Psilocybin, MDMA, and ibogaine remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review but produce no approval yet (FDA). Washington's posture is unusually well matched to this federal pathway: its existing access vehicle (SB 5263) is a scaled-down University of Washington pilot limited to veterans and first responders and conditioned on FDA-approved psilocybin therapy, so the state has effectively pre-wired itself to switch on once FDA approval lands. The 2026 medical psilocybin expansion (Sen. Salomon's SB 5921) did not pass, so for now Washington stays in the narrow federally-contingent lane rather than a broad state-regulated one.

Harm reduction. SAMHSA guidance (April 24, 2026) bars federal funds for fentanyl test strips, clean syringes, and sterile water, while still supporting naloxone. This hits Washington squarely, because the state runs a robust harm-reduction infrastructure (legal syringe services, broadly distributed naloxone, legal fentanyl test strips) and operates in a post-Blake recriminalization environment where possession is a gross misdemeanor with a treatment-diversion overlay. Test strips and syringe services in Washington now lose federal dollars and must lean on state and local funding to continue, even though they remain legal under state law, so the federal cut is a funding attack on services the state still endorses. Naloxone access (free at pharmacies for Apple Health enrollees, mail order, vending machines) stays federally supported.

Patient access and rights

This section covers what Washington law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Washington enacted a Ryan's Law protection in 2026. House Bill 2152, signed March 11, 2026 and in force since June 11, 2026, allows a qualifying patient to use medical cannabis in a health care facility, though not by smoking or vaping, and facility rules apply. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), with Pennsylvania's bill pending.

Broader protections: Washington protects a patient in two areas. It protects parental and custody rights under Revised Code of Washington Section 69.51A.120, and it protects placement on an organ transplant list under Section 69.51A.110. But Washington does not protect employment; Section 69.51A.060 declines to require an employer to accommodate medical use. A review of the cannabis chapter found no protection for housing, school enrollment, or general medical care, and the law expressly disclaims a right to care.

Out-of-state patients: Washington offers no medical reciprocity; adults 21 and over use the adult-use market.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine, and it creates no hospital-use right or employment, housing, custody, transplant, or school protection; the protections and limits above are creatures of Washington law, not federal law.

Sources: Washington's Ryan's Law, House Bill 2152 (2026); parental and custody rights, Revised Code of Washington Section 69.51A.120; organ transplants, Section 69.51A.110; the employment provision, Section 69.51A.060.

Analysis: the enclosure read in depth

Washington is a textbook federal-plus-state enclosure case, which is why the score sits at 4 and not lower.

Who is fenced out. Adults who want to grow their own are fenced out entirely: there is no adult-use home grow (SB 6204 died in 2026), so the only legal path to flower runs through a capped, heavily taxed retail system. New and small operators are fenced out by a frozen general-license pipeline (retail cap reported around 500) and a brutally oversubscribed equity lottery (880 registrants for 69 licenses in 2025), and the few who get in face the nation's highest excise plus federal 280E with no banking, which structurally favors anyone already capitalized. Independent hemp brands are fenced out twice over, by SB 5367 at the state level and by the November 12, 2026 federal total-THC ban at the national level. Harm-reduction providers are squeezed by the April 2026 SAMHSA funding cut even though their services stay legal.

Who consolidates. The winners are licensed incumbents with capital and access to scarce licenses, plus the state's own tax base, which the home-grow opposition has openly defended. The state-plus-federal interaction tightens the screws in the same direction: 280E (federal) raises effective tax, the high state excise raises it again, stalled SAFER (federal) denies banking, the license cap (state) blocks entry, and the hemp cliff (federal) reinforces SB 5367 (state). Almost every lever points toward consolidation around large, banked, licensed players and away from small actors, home growers, and the gray-market hemp fringe, which is the enclosure thesis in concentrated form.

Where commons counter-moves are present. Two genuine open-access pressures keep this from a 5. First, Blake-record relief is a real decommodifying counter-move: vacated convictions plus roughly $100 million set aside to refund fines and fees returns standing and money to people the old regime had stripped. Second, Washington's harm-reduction infrastructure remains strong and legal under state law even as federal funding retreats, and an active reform bloc keeps pushing home grow and psilocybin access for the next session. These are commons-protecting forces. But they operate alongside, not against, the consolidation of the commercial market.

Justifying the score. The dominant trend is enclosure: capped licenses, no adult home grow, the highest excise in the country, federal 280E with no relief for the recreational majority, no banking, and a hemp channel rule now backstopped by a federal ban. The counterweights (record relief, harm reduction, a persistent reform bloc) are real and active, which is what holds the score at 4 rather than pushing it to a maximal 5.

What to watch. Whether the 2027 long session revives adult home grow (an SB 6204 successor) or medical psilocybin (an SB 5921 successor); any FDA psilocybin approval that would activate Washington's pre-wired pilot; whether the state and localities backfill the SAMHSA-cut harm-reduction funding; WSLCB conformance rulemaking, if any, around the November 12, 2026 federal hemp standard; and any movement on SAFER Banking that would relieve the cash-only burden.

Active legislation (2026)

The 2026 regular session was a short 60-day session that convened January 12, 2026 and adjourned sine die March 12, 2026. As of this brief (June 2026), the session is over, so the drug-policy bills below did not advance to enactment and are inactive unless carried into a future session. This list is not exhaustive, for the long tail use the live trackers linked below.

Bill	Title/Topic	Chamber	Status	Sponsor(s)
SB 6204	Legalize home cultivation of cannabis (up to 6 plants per adult, 15 per housing unit)	Senate	Did not pass, advanced from Labor and Commerce Committee then placed in Senate Rules "X" file, died at session end	Sponsors reported as Sens. Saldaña, Frame, Nobles (unconfirmed, verify on bill page)
SB 5921	Washington medical psilocybin act, Department of Health regulated program, effective July 1, 2028 if enacted	Senate	Prefiled Dec 19, 2025, did not pass in 2026	Sen. Jesse Salomon (D)
SB 5201	Psychedelics / psilocybin therapeutic access (carryover from 2025)	Senate	Did not pass in biennium (status unconfirmed, verify on tracker)	Unconfirmed

Live trackers for the full set of cannabis, hemp, psychedelic, and drug-policy bills: WA Legislature bill search, LegiScan Washington, Marijuana Moment, Cannabis Observer WA. This table is not exhaustive.

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →